Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory B-cell ALL”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02484430
What this trial is testing

Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

Who this might be right for
B Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative+3 more
National Cancer Institute (NCI) 16
Testing effectiveness (Phase 2)Study completedNCT01068392
What this trial is testing

Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)

Who this might be right for
B-cell Lymphomas
Dong-A University Hospital 42
Early research (Phase 1)Study completedNCT02222688
What this trial is testing

UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia

Who this might be right for
Chronic Lymphocytic Leukemia
Thomas Kipps 26
Early research (Phase 1)Study completedNCT00005946
What this trial is testing

Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
University of Maryland, Baltimore
Testing effectiveness (Phase 2)Study completedNCT02332980
What this trial is testing

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue+20 more
Mayo Clinic 65
Early research (Phase 1)Study completedNCT01410513
What this trial is testing

Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

Who this might be right for
Indolent Non-Hodgkin LymphomaMantle Cell LymphomaChronic Lymphocytic Leukemia
Sanofi 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT02846623
What this trial is testing

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

Who this might be right for
Chronic Lymphocytic LeukemiaRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic Leukemia+2 more
M.D. Anderson Cancer Center 50
Early research (Phase 1)Active Not RecruitingNCT05362773
What this trial is testing

MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Leukemia, Acute MyeloidMyelodysplastic SyndromesClassical Hodgkin Lymphoma+5 more
MacroGenics 130
Testing effectiveness (Phase 2)Study completedNCT01030900
What this trial is testing

Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

Who this might be right for
Hodgkin LymphomaDiffuse Large B-Cell Lymphoma
National Cancer Institute (NCI) 50
Testing effectiveness (Phase 2)Study completedNCT00047021
What this trial is testing

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma

Who this might be right for
LeukemiaLymphoma
Case Comprehensive Cancer Center 3
Not applicableStudy completedNCT00996047
What this trial is testing

S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

Who this might be right for
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
SWOG Cancer Research Network 3,341
Testing effectiveness (Phase 2)UnknownNCT03258047
What this trial is testing

Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

Who this might be right for
B Cell Lymphoma
First Affiliated Hospital of Zhejiang University 60
Testing effectiveness (Phase 2)Looking for participantsNCT05745714
What this trial is testing

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Who this might be right for
Acute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent+2 more
Princess Maxima Center for Pediatric Oncology
Early research (Phase 1)WithdrawnNCT02640833
What this trial is testing

Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaNon-Hodgkin Lymphoma
AbbVie
Early research (Phase 1)WithdrawnNCT04279938
What this trial is testing

A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL

Who this might be right for
Relapsed or Refractory Diffuse Large B-cell Lymphoma
Royal Marsden NHS Foundation Trust
Testing effectiveness (Phase 2)Ended earlyNCT01685021
What this trial is testing

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)

Who this might be right for
Acute Lymphoblastic Leukemia
MorphoSys AG 22
Early research (Phase 1)Study completedNCT02594384
What this trial is testing

A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic
OrphAI Therapeutics 62
Testing effectiveness (Phase 2)UnknownNCT04500561
What this trial is testing

YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial

Who this might be right for
Diffuse Large B Cell Lymphoma
Shanghai YingLi Pharmaceutical Co. Ltd. 28
Early research (Phase 1)Study completedNCT04103905
What this trial is testing

MIL62 in Treatment of CD20 Positive B-cell Lymphomas

Who this might be right for
CD20-positive B Cell Non-Hodgkin Lymphoma
Beijing Mabworks Biotech Co., Ltd. 27
Testing effectiveness (Phase 2)Looking for participantsNCT07473167
What this trial is testing

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

Who this might be right for
Relapsed Large B-cell LymphomaRefractory Large B-cell LymphomaDiffuse Large B-cell Lymphoma (DLBCL)+3 more
TICAROS Co., Ltd. 98
Next Page
26